David Steensma: Randomized STIMULUS-MDS1 trial didn’t meet endpoint

David Steensma, Associate professor at Harvard Medical School and faculty member in the leukemia program at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, shared a post on X/Twitter:

“Our X2105 sabatolimab (MBG453, anti-TIM3 MoAb)+HMA trial in MDSsm and CMML led by Andrew Brunner and Andrew Wei just published American Journal of Hematology. Randomized STIMULUS-MDS1 trial didn’t meet endpoint; results of larger randomized STIMULUS-MDS2 OS trial are awaited.”

For details click here.
Source: David Steensma/Twitter